Findings

What do systematic reviews say?

6 questions · 12 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 16.7%Moderate 5 · 41.7%High 5 · 41.7%

Overall survival ( · people with HGG

Anti‐angiogenic therapy showed no clear difference in overall survival ( compared with no anti‐angiogenic therapy (high certainty).

4 findings from 1 review

Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.95 [0.88, 1.02]
11 studies · 3743 participants
High
Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.93 [0.86, 1.02]
8 studies · 2833 participants
High
Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.99 [0.85, 1.16]
3 studies · 910 participants
Moderate

Show 1 more finding

Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.92 [0.85, 1]
11 studies · 3506 participants
Low

Progression‐free survival · people with HGG

Anti‐angiogenic therapy leads to lower progression‐free survival ( compared with no anti‐angiogenic therapy (high certainty).

4 findings from 1 review

Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.73 [0.68, 0.79]
10 studies · 3595 participants
High
Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.75 [0.69, 0.82]
8 studies · 2833 participants
High
Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.64 [0.54, 0.76]
2 studies · 762 participants
Moderate

Show 1 more finding

Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.72 [0.66, 0.77]
10 studies · 3464 participants
High

Overall survival† · people with cutaneous melanoma

Anti‐angiogenic drugs plus chemotherapy probably leads to lower overall survival† compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.6 [0.45, 0.81]
324 participants
Moderate

Progression‐free survival · people with cutaneous melanoma

Anti‐angiogenic drugs plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.69 [0.52, 0.92]
324 participants
Moderate

Tumour response · people with cutaneous melanoma

Anti‐angiogenic drugs plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.71 [0.96, 3.03]
324 participants
Moderate

Toxicity (≥ G3) · people with cutaneous melanoma

Anti‐angiogenic drugs plus chemotherapy showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 0.68 [0.09, 5.32]
324 participants
Low